Cargando…

Analysis of the current Covid-19 infection and vaccination status in patients with neurofibromatosis type 1

BACKGROUND: To investigate the common symptoms after Covid-19 infection, characteristics of adverse events after vaccination, changes in clinical manifestations related to Neurofibromatosis type 1 (NF1), as well as the current vaccination status and factors related to vaccine hesitation among NF1 pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ge, Lingling, Gu, Yihui, Wang, Wei, Wei, Chengjiang, Wang, Zhichao, Li, Qingfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	China Medical Cosmetology Press Co. Ltd. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028342/ http://dx.doi.org/10.1016/j.cjprs.2023.03.003

Ejemplares similares

Efficacy and Safety of Trametinib in Neurofibromatosis Type 1-Associated Plexiform Neurofibroma and Low-Grade Glioma: A Systematic Review and Meta-Analysis
por: Wang, Dun, et al.
Publicado: (2022)

Concurrent inhibition of FAK/SRC and MEK overcomes MEK inhibitor resistance in Neurofibromatosis Type I related malignant peripheral nerve sheath tumors
por: Gu, Yihui, et al.
Publicado: (2022)

Knockdown of NCOR2 Inhibits Cell Proliferation via BDNF/TrkB/ERK in NF1-Derived MPNSTs
por: Li, Yuehua, et al.
Publicado: (2022)

Photonic hyperthermia of malignant peripheral nerve sheath tumors at the third near-infrared biowindow
por: Gu, Yihui, et al.
Publicado: (2022)

Distribution Patterns (7B Rule) and Characteristics of Large Congenital Melanocytic Nevi: A Retrospective Cohort Study in China
por: Wang, Huijing, et al.
Publicado: (2021)

Preclinical Assessment of MEK Inhibitors for Malignant Peripheral Nerve Sheath Tumors Reveals Differences in Efficacy and Adaptive Response
por: Gu, Yihui, et al.
Publicado: (2022)

Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis
por: Tamura, Ryota
Publicado: (2021)

Current concepts of neurofibromatosis type 1: pathophysiology and treatment
por: Choi, Jaemin, et al.
Publicado: (2022)

Impacts of NF1 Gene Mutations and Genetic Modifiers in Neurofibromatosis Type 1
por: Wang, Wei, et al.
Publicado: (2021)

Neutralizing antibodies against SARS-CoV-2 virus after vaccination in patients with neurofibromatosis type 1
por: Ruan, Qiao-ling, et al.
Publicado: (2023)

COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis
por: Banerjee, Jineta, et al.
Publicado: (2023)

The Current Status of COVID-19 Vaccines
por: Lundstrom, Kenneth
Publicado: (2020)

Pheochromocytoma associated with neurofibromatosis type 1: concepts and current trends
por: Zografos, George N, et al.
Publicado: (2010)

Current progress in genomics and targeted therapies for neurofibromatosis type 2
por: Hiruta, Ryo, et al.
Publicado: (2023)

COVID-19 Infection in Children and Infants: Current Status on Therapies and Vaccines
por: Malcangi, Giuseppina, et al.
Publicado: (2022)

Seizures in children with neurofibromatosis type 1: is neurofibromatosis type 1 enough?
por: Santoro, Claudia, et al.
Publicado: (2018)

Neurofibromatosis type 1
por: Mançano, Alexandre Dias
Publicado: (2022)

Increased risk of breast cancer in neurofibromatosis type 1: current insights
por: Howell, Sacha J, et al.
Publicado: (2017)

Translating current basic research into future therapies for neurofibromatosis type 1
por: Brosseau, Jean-Philippe, et al.
Publicado: (2020)

Neurofibromatosis: chronological history and current issues*
por: Antônio, João Roberto, et al.
Publicado: (2013)

The role of macrophages in the formation of hypertrophic scars and keloids
por: Xu, Xiangwen, et al.
Publicado: (2020)

Cranio-orbital-temporal neurofibromatosis: An uncommon subtype of neurofibromatosis type-1
por: Acharya, Nibedita, et al.
Publicado: (2014)

Tropomyosin receptor kinase B (TrkB) signalling: targeted therapy in neurogenic tumours
por: Li, Yuehua, et al.
Publicado: (2022)

Plexiform neurofibromatosis type 1
por: Sharma, Surendra K., et al.
Publicado: (2016)

Neurofibromatosis Type 1 in the Mandible
por: Uchiyama, Yuka, et al.
Publicado: (2018)

Hemostasis and Type 1 Neurofibromatosis
por: Niddam, Jeremy, et al.
Publicado: (2017)

Pharmacological Effects of Verticine: Current Status
por: Yin, Zhenhua, et al.
Publicado: (2019)

The current second wave and COVID-19 vaccination status in India
por: Chakraborty, Chiranjib, et al.
Publicado: (2021)

The current status of COVID-19 vaccines. A scoping review
por: Rueda-Fernández, Manuel, et al.
Publicado: (2022)

Current clinical status of new COVID-19 vaccines and immunotherapy
por: Nagpal, Diksha, et al.
Publicado: (2022)

Current update on the visual outcome of optic pathway glioma associated with neurofibromatosis type-1
por: Zeid, Janice Lasky
Publicado: (2022)

Neurofibromatosis Type 1-Associated Optic Pathway Gliomas: Current Challenges and Future Prospects
por: Tang, Yunshuo, et al.
Publicado: (2023)

A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2
por: Tamura, Ryota, et al.
Publicado: (2019)

Effect of age and neurofibromatosis type 1 status on white matter integrity in the optic radiations
por: de Blank, Peter, et al.
Publicado: (2020)

Systematic Review of Pediatric Brain Tumors in Neurofibromatosis Type 1: Status of Gene Therapy
por: Thomas, Sonu, et al.
Publicado: (2022)

Streptococcus pyogenes: Pathogenesis and the Current Status of Vaccines
por: Wang, Jiachao, et al.
Publicado: (2023)

Clinical manifestations of COVID-19 infection in dialysis patients and protective effect of COVID-19 vaccine
por: Zhang, Xuehan, et al.
Publicado: (2023)

Statins, bone, and neurofibromatosis type 1
por: Korf, Bruce R
Publicado: (2008)

Moyamoya syndrome and neurofibromatosis type 1
por: Vargiami, Euthymia, et al.
Publicado: (2014)

Neurofibromatosis Type 1 with Bladder Involvement
por: Üre, Iyimser, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_pe03b6ani2b64qjocncksde2vb